Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball' - 2I thought I knew the night sky, but what I saw from the Canary Islands left me speechless
- 3U.S. overhauls childhood vaccine schedule, recommends fewer shots
- 4Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 5Nutrient Rich Organic products: Lift Your Wellbeing
- Best Exciting ride: Which One Rushes You the Most?
- Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 4 Coolers for Present day Kitchens
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Pick Your Favored kind of sandwich
- Humpback whale stranded on Germany's Baltic coast frees itself
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
